Alentis Appoints Jonathan Freve CFO
Jon brings more than 25 years of financial experience in the biotech sector BASEL, Switzerland – Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today that Jonathan (Jon) Freve has been appointed Chief Financial Officer effective immediately. Roberto Iacone, CEO of Alentis said, “Jon has a proven track record in successful IPOs, secondary offerings and … Continue reading Alentis Appoints Jonathan Freve CFO